Abnova and Clearbridge BioMedics Accelerate Circulating Tumor Cell System into the Research and In Vitro Diagnostic Markets
“CTCs represent one of three important pillars of system integration for Abnova in the hierarchical organization and interrogation of tissue, cell, and protein,” said Dr. Wilber Huang, President and CEO of Abnova. “Clearbridge BioMedics has elegantly engineered a breakthrough CTC platform, which is unmatched by the competitors, specifically the ability to preserve cell viability after isolation. Up until now, the access to tissue samples is confined to the initial biopsy for diagnosis and staging workup followed by pathological confirmation of resected tissues. The opportunity for non-invasive “liquid biopsy” has tremendous potential in disease management, especially in molecular staging, personalized therapy and recurrence monitoring. Abnova has a plethora of research antibodies and FISH probes to catapult the research market, in addition to a full pipeline of novel IVD biomarkers under development, which are applicable to CTC platform including prostate, ovarian, and lung cancers."
Most read news
Other news from the department research and development
Get the analytics and lab tech industry in your inbox
From now on, don't miss a thing: Our newsletter for analytics and lab technology brings you up to date every Tuesday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous